Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics
Today's Latest Price: $100.50 USD
Oct 30 4:00pm Add RARE to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
RARE Stock Summary The ratio of debt to operating expenses for Ultragenyx Pharmaceutical Inc is higher than it is for about only 9.09% of US stocks. RARE's price/sales ratio is 28.52; that's higher than the P/S ratio of 94.17% of US stocks. Revenue growth over the past 12 months for Ultragenyx Pharmaceutical Inc comes in at 154.89%, a number that bests 96.23% of the US stocks we're tracking. Stocks that are quantitatively similar to RARE, based on their financial statements, market capitalization, and price volatility, are BLUE, AGIO, FPRX, RGNX, and APTX. Visit RARE's SEC page to see the company's official filings. To visit the company's web site, go to www.ultragenyx.com.
RARE Price/Volume Stats
Ultragenyx Pharmaceutical Inc. (RARE) Company Bio
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.
RARE Latest News Stream
All News Types
Barron's Commentary Corp. News Debt Offering Downgrade Earnings Insider Buying M&A Mgmt Change New Coverage (Bearish) New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Resumes Coverage (Bullish) Stock Offering Upgrade
Loading, please wait...
Latest RARE News From Around the Web
Below are the latest news stories about Ultragenyx Pharmaceutical Inc that investors may wish to consider to help them evaluate RARE as an investment opportunity.
Ultragenyx Pharmaceutical (RARE) has appointed Mardi C. Dier as EVP and CFO, effective November 2, 2020.Ms. Dier will succeed Ms. Sharp, who will remain as CFO until November and will consult for the company for six months after for smooth transition. Ms. Dier joins Ultragenyx from Portola Pharmaceuticals, where she...
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2020 Earnings Conference Call July 30, 2020 5:00 PM ET Company Participants Joshua Higa - Director, Investor Relations and Corporate Communications Emil Kakkis - Chief Executive Officer and President Erik Harris - Chief Commercial Officer Shalini Sharp - Chief Financial Officer Camille Bedrosian - Chief...
RARE earnings call for the period ending June 30, 2020.
Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.
Ultragenyx (RARE) delivered earnings and revenue surprises of 47.44% and 53.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Read More 'RARE' Stories Here
RARE Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.9805 seconds.